Cardiac complications of systemic sclerosis: Recent progress in diagnosis

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 696-703

  Boueiz, Adel ^a   Mathai, Stephen C ^a   Hummers, Laura K ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

pulmonary arterial hypertension; scleroderma; scleroderma heart disease; systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TECHNETIUM 99M;

AORTA STENOSIS; AORTA VALVE REGURGITATION; ATHEROSCLEROSIS; AUTOPSY; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART CATHETERIZATION; HEART DISEASE; HEART INDEX; HEART INFARCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART STROKE VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICULOGRAPHY; HUMAN; LIFE EXPECTANCY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MITRAL VALVE REGURGITATION; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULSE PRESSURE; QUALITY OF LIFE; REVIEW; SCINTISCANNING; SCLERODERMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STARLING LAW; STRESS ECHOCARDIOGRAPHY; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY;

CARDIOMYOPATHIES; FIBROSIS; HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 77958031972     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833dfbd8     Document Type: Review

References (97)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367:1683-1691.
2. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-2255.
3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
4. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10.
5. Follansbee WP, Miller TR, Curtiss EI, et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990; 17:656-662.
6. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58:1803-1809.
7. Medsger TA Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26:647-660.
8. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81:139-153.
9. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am 1996; 22:841-860.
10. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am 2008; 34:181-190; viii.
11. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976; 53:483-490.
12. Fernandes F, Ramires FJ, Arteaga E, et al. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyo-cardial biopsy study. J Card Fail 2003; 9:311-317.
13. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clin-icopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 1978; 95:563-569.
14. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 2006; 45:1395-1398.
15. Derk CT, Jimenez SA. Acute myocardial infarction in systemic sclerosis patients: a case series. Clin Rheumatol 2007; 26:965-968.
16. Allanore Y, Meune C, Kahan A. Outcome measures for heart involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl 5): v51-v53.
17. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroder-ma. Curr Opin Rheumatol 2002; 14:686-693.
18. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008; 34:57-71; vi.
19. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroder-ma. Autoimmun Rev 2007; 6:520-523.
20. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485-494.
21. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67:110-116.
22. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1093.
23. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multi-center study. Arthritis Rheum 2005; 52:3792-3800.
24. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary healthcare level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125-2132.
25. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54:3043-3050.
26. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123:344-350.
27. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27:1485-1494.
28. Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005; 24:1626-1631.
29. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65:1336-1340.
30. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006; 36 (Suppl 3):10-15.
31. Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124:2098-2104.
32. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29:469-475.
33. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
34. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16:13-18.
35. MacNee W. Right ventricular function in cor pulmonale. Cardiology 1988; 75 (Suppl 1):30-40.
36. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004; 3:339-352.
37. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 13S-24S.
38. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. J Am Med Assoc 2002; 288:2144-2150.
39. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269.
40. Ferri C, Bernini L, Bongiorni MG, et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum 1985; 28:1259-1266.
41. Tongers J, Schwerdtfeger B, Klein G, etal. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153:127-132.
42. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114:1883-1891.
43. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-asso-ciated pulmonary arterial hypertension in the modern treatment era. Am JRespir Crit Care Med 2009; 179:151-157.
44. Campo A, Mathai SC, Le Pavec J, etal. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit CareMed. 2010. Mar 25 [Epub ahead of print]
45. Pokreisz P. Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited. Eur Heart J Suppl 2007; 9 (Suppl H):H75-H84.
46. Bristow MR, Zisman LS, Lowes BD, et al. The pressure-overloaded right ventricle in pulmonary hypertension. Chest 1998; 114 (1 Suppl):101S-106S.
47. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5:80-93.
48. Montisci R, Vacca A, Garau P, et al. Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis 2003; 62:890-893.
49. Belloli L, Carlo-Stella N, Ciocia G, et al. Myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47:1070-1072.
50. MurataI,Takenaka K, ShinoharaS, etal. Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients. Am Heart J 1998; 135 (6 Pt 1):960-969.
51. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28:2454-2459.
52. Kuwana M, Okano Y, Kaburaki J, etal. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994; 37:902-906.
53. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91:1127-1134.
54. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89:463-465.
55. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593.
56. Stanek B, Frey B, Hulsmann M, etal. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38:436-442.
57. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131:402-409.
58. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764-770.
59. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonaryhypertension. Eur Respir J 2010; 35:95-104.
60. Fijalkowska A, Kurzyna M, Torbicki A, etal. Serum N-terminal brain natriureticpeptide as a prognostic parameter in patients with pulmonary hypertension.Chest 2006; 129:1313-1321.
61. van Wolferen SA, Boonstra A, Marcus JT, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006; 92:1860-1861.
62. Souza R, Jardim C, Martins B, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005; 21:907-911.
63. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 2008; 27:655-658.
64. Smith JW, Clements PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS): correlation with hemodynamic and postmortem studies. Am J Med 1979; 66:28-33.
65. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67:31-36.
66. Sulli A, Ghio M, Bezante GP, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004; 43:505-509.
67. Vacca A, Montisci R, Cauli A, et al. Evaluation of cardiac functional abnormalities in systemic sclerosis by dobutamine stress echocardiography: a myocardial echostress scleroderma pattern. Ann Rheum Dis 2006; 65:1669-1670.
68. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997; 10:169-178.
69. Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of noninvasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr 2007; 8:317-321.
70. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107:526-531.
71. Gupta S, Khan F, Shapiro M, et al. The associations between tricuspid annular plane systolic excursion (TAPSE), ventricular dyssynchrony, and ventricular interaction in heart failure patients. Eur J Echocardiogr 2008; 9:766-771.
72. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174:1034-1041.
73. Brown L, Shehata M, Osman N, et al. Right ventricular structure and function in pulmonary arterial hypertension associated with systemic sclerosis. Proc Am Thorac Soc 2008; A442.
74. Yu CM, Sanderson JE, Marwick TH, Oh JK. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007; 49:1903-1914.
75. Gondi S, Dokainish H. Right ventricular tissue Doppler and strain imaging: ready for clinical use? Echocardiography 2007; 24:522-532.
76. D'Andrea A, Stisi S, Bellissimo S, et al. Early impairment of myocardial function in systemic sclerosis: noninvasive assessment by Doppler myocar-dial and strain rate imaging. Eur J Echocardiogr 2005; 6:407-418.
77. Kepez A, Akdogan A, Sade LE, et al. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography 2008; 25:191-197.
78. Meune C, Allanore Y, Devaux JY, et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004; 31:1941-1945.
79. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006; 45 (Suppl 4):iv14-iv17.
80. Nakajima K, Kawano M, Hasegawa M, etal. Myocardial damages in systemic sclerosis detected by gated myocardial perfusion SPECT and sympathetic imaging. Circ J 2006; 70:1481-1487.
81. Steen VD, Follansbee WP, Conte CG, et al. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 1996; 39:677-681.
82. Kahan A, Devaux JY, Amor B, et al. Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis 1986; 45:718-725.
83. Kahan A, Devaux JY, Amor B, etal. Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol 1988; 15:1395-1400.
84. Kahan A, Devaux JY, Amor B, et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 1990; 47:483-489.
85. Kahan A, Nitenberg A, Foult JM, etal. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985; 28:637-646.
86. Kahan A, Devaux JY, Amor B, et al. Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis. J Cardiovasc Pharmacol 1990; 15:249-253.
87. Boxt LM. Radiology of the right ventricle. Radiol Clin North Am 1999; 37:379-400.
88. Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007; 34:2431-2437.
89. HachullaAL, Launay D,Gaxotte V, etal. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68:1878-1884.
90. Hagger D, Condliffe R, Woodhouse N, et al. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemicsclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford)2009; 48:1137-1142.
91. Plastiras SC, Kelekis N, Tzelepis GE. Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. N Engl J Med 2006; 354:2194-2196.
92. Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56:3827-3836.
93. WilkinsMR, Paul GA, Strange JW, etal. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171:1292-1297.
94. Overbeek MJ, Lankhaar JW, Westerhof N, et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31:1160-1166.
95. Liangos O, Neure L, Kuhl U, et al. The possible role of myocardial biopsy in systemic sclerosis. Rheumatology (Oxford) 2000; 39:674-679.
96. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993; 125:194-203.
97. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37:485-494.